Lectin-Based Urinary PSA Detection for Prostate Cancer Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prostate cancer, particularly in the gray zone of blood PSA levels between 4 ng/mL and 10 ng/mL, are invasive and ineffective in distinguishing between prostate cancer and benign conditions, leading to unnecessary biopsies and low detection accuracy.
Innovation Solution
A method involving a lectin capable of binding to an α1→6 fucose sugar chain is used to react with urinary PSA, where the lectin has specific binding constants for different sugar chains, allowing for the detection of high-risk prostate cancer by measuring the PSA-lectin complex levels, which correlates with Gleason score and malignancy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood PSA test is used for prostate cancer screening, then detection coverage is improved, but detection accuracy and ability to distinguish high-risk cancer deteriorates
Solution Approach 1:
The invention segments the PSA measurement approach by switching from blood PSA to urinary PSA, and further segments the detection methodology by introducing lectin-based binding assays that specifically target glycosylated PSA forms. This segmentation allows differentiation between benign and malignant conditions that cannot be distinguished by conventional blood PSA alone.
Solution Approach 2:
The invention introduces lectins as intermediary molecules that mediate between the PSA biomarker and the detection system. These lectins specifically bind to glycosylated PSA forms, serving as intermediaries that enable accurate detection and risk stratification without requiring invasive biopsy procedures.
2Measurement precision
If prostate biopsy is performed for definitive diagnosis, then diagnostic accuracy is improved, but invasiveness and patient burden increase
Solution Approach 1:
The invention performs preliminary risk stratification using non-invasive urinary PSA lectin binding assays before conducting invasive biopsy procedures. By preliminarily identifying high-risk patients through glycosylation pattern analysis, the system enables targeted biopsy only for those who truly need it, reducing unnecessary invasive procedures.
Solution Approach 2:
The invention replaces the mechanical invasive biopsy system with a biochemical detection system based on lectin-PSA binding. This substitution uses molecular recognition events instead of physical tissue sampling, providing diagnostic information through non-invasive urinary analysis.
3Ease of operation
If conventional PSA measurement is used, then simplicity is maintained, but ability to assess malignancy risk deteriorates
Solution Approach 1:
The invention changes the measurement parameter from total PSA concentration to lectin binding activity, which reflects the glycosylation status of PSA. This parameter change provides additional information about malignancy risk while maintaining operational simplicity through established lectin binding assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a non-invasive, accurate method for detecting high-risk prostate cancer before biopsy, improving the distinction between cancer and benign conditions, and reducing unnecessary procedures by utilizing urinary PSA rather than blood PSA, resulting in higher detection accuracy and clearer malignancy assessment.
Implementation Method 1
a lectin capable of binding to an α1→6 fucose sugar chain... reacting urinary PSA with the lectin
Data Source
AI summary
[Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test.[Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose α1→6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M−1 or more (at 25° C.) for an α1→6 fucose sugar chain No. 405. The fucose α1→6 affinitive lectin is preferably (2) a fucose α1→6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M−1 or less (at 25° C.) for a sugar chain No. 003 that does not contain α1→6 fucose and a glycolipid-type sugar chain No. 909 that does not contain α1→6 fucose.